Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Saved in:
| Title: | Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. |
|---|---|
| Authors: | Pagano G; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. Gennaro.Pagano@Roche.com.; University of Exeter Medical School, London, UK. Gennaro.Pagano@Roche.com., Taylor KI; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Anzures Cabrera J; Roche Products Ltd, Welwyn Garden City, UK., Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA., Postuma RB; Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK., Stocchi F; The Institute for Research and Medical Care (IRCCS) San Raffaele Pisana, University San Raffaele Roma, Rome, Italy., Brockmann K; Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany., Svoboda H; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Diagnostics GmbH, Penzberg, Germany., Trundell D; Roche Products Ltd, Welwyn Garden City, UK., Monnet A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Doody R; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Fontoura P; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Kerchner GA; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Brundin P; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland., Nikolcheva T; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Bonni A; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. |
| Corporate Authors: | PASADENA Investigators, Prasinezumab Study Group |
| Source: | Nature medicine [Nat Med] 2024 Apr; Vol. 30 (4), pp. 1096-1103. Date of Electronic Publication: 2024 Apr 15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38622249 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pagano+G%22">Pagano G</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. Gennaro.Pagano@Roche.com.; University of Exeter Medical School, London, UK. Gennaro.Pagano@Roche.com.<br /><searchLink fieldCode="AU" term="%22Taylor+KI%22">Taylor KI</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Anzures+Cabrera+J%22">Anzures Cabrera J</searchLink>; Roche Products Ltd, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Simuni+T%22">Simuni T</searchLink>; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Marek+K%22">Marek K</searchLink>; Institute for Neurodegenerative Disorders, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Postuma+RB%22">Postuma RB</searchLink>; Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.<br /><searchLink fieldCode="AU" term="%22Pavese+N%22">Pavese N</searchLink>; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Stocchi+F%22">Stocchi F</searchLink>; The Institute for Research and Medical Care (IRCCS) San Raffaele Pisana, University San Raffaele Roma, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Brockmann+K%22">Brockmann K</searchLink>; Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Svoboda+H%22">Svoboda H</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.; Roche Diagnostics GmbH, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Trundell+D%22">Trundell D</searchLink>; Roche Products Ltd, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Monnet+A%22">Monnet A</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Doody+R%22">Doody R</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Fontoura+P%22">Fontoura P</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kerchner+GA%22">Kerchner GA</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Brundin+P%22">Brundin P</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Nikolcheva+T%22">Nikolcheva T</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bonni+A%22">Bonni A</searchLink>; Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22PASADENA+Investigators%22">PASADENA Investigators</searchLink><br /><searchLink fieldCode="CA" term="%22Prasinezumab+Study+Group%22">Prasinezumab Study Group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2024 Apr; Vol. 30 (4), pp. 1096-1103. <i>Date of Electronic Publication: </i>2024 Apr 15. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38622249 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41591-024-02886-y Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1096 Titles: – TitleFull: Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pagano G – PersonEntity: Name: NameFull: Taylor KI – PersonEntity: Name: NameFull: Anzures Cabrera J – PersonEntity: Name: NameFull: Simuni T – PersonEntity: Name: NameFull: Marek K – PersonEntity: Name: NameFull: Postuma RB – PersonEntity: Name: NameFull: Pavese N – PersonEntity: Name: NameFull: Stocchi F – PersonEntity: Name: NameFull: Brockmann K – PersonEntity: Name: NameFull: Svoboda H – PersonEntity: Name: NameFull: Trundell D – PersonEntity: Name: NameFull: Monnet A – PersonEntity: Name: NameFull: Doody R – PersonEntity: Name: NameFull: Fontoura P – PersonEntity: Name: NameFull: Kerchner GA – PersonEntity: Name: NameFull: Brundin P – PersonEntity: Name: NameFull: Nikolcheva T – PersonEntity: Name: NameFull: Bonni A IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2024 Apr Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1546-170X Numbering: – Type: volume Value: 30 – Type: issue Value: 4 Titles: – TitleFull: Nature medicine Type: main |
| ResultId | 1 |